Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.

Aditi Sinha,Georgie Mathew,Arushi Arushi,Srinivasavaradan Govindarajan, Kshetrimayum Ghanapriya,Neetu Grewal, Khushboo Rai,Megha Brijwal, Sree Laya Kalluru,Prachi Tewari, Angeli Misra,Priyanka Khandelwal,Pankaj Hari,Arvind Bagga

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association（2023）

引用 6|浏览8

暂无评分

摘要

Sequential therapy with RTX effectively reduces relapses in patients with difficult-to-treat steroid- and/or CNI-dependent or CNI-refractory nephrotic syndrome. Therapy is associated with high rates of hypogammaglobulinemia and infusion reactions.

查看译文

关键词

B cell–depleting therapy,focal segmental glomerulosclerosis,hypogammaglobulinemia,minimal change,proteinuria

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要